Financial Performance - The company's operating revenue for the first half of 2023 was CNY 959,574,571.06, a decrease of 9.91% compared to CNY 1,065,134,639.52 in the same period last year[23]. - The net profit attributable to shareholders was CNY 9,546,078.21, a significant improvement from a loss of CNY 18,989,077.33 in the previous year[23]. - The net cash flow from operating activities decreased by 71.72% to CNY 18,501,155.36 from CNY 65,420,601.39 in the same period last year[23]. - The basic earnings per share increased to CNY 0.0074 from a loss of CNY 0.0146 in the previous year[23]. - The company's total revenue for the reporting period was CNY 959,574,571.06, representing a decrease of 9.91% compared to CNY 1,065,134,639.52 in the previous year[61]. - The pharmaceutical segment accounted for 89.80% of total revenue, with a revenue of CNY 861,707,857.17, down 7.84% from CNY 934,977,828.85[62]. - The revenue from medical devices plummeted by 98.01%, falling to CNY 786,136.77 from CNY 39,546,067.01 in the previous year[62]. - The revenue from the gastrointestinal product "肠胃康" increased by 45.82%, reaching CNY 134,950,876.21, compared to CNY 92,545,013.07 in the previous year[62]. - The revenue from the cephalosporin series was ¥224,594,230, with a gross profit margin of 67.34%, showing an 8.56% increase in revenue year-on-year[63]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,754,357,617.56, reflecting a growth of 5.28% from CNY 7,365,442,827.12 at the end of the previous year[23]. - The net assets attributable to shareholders increased by 0.53% to CNY 2,176,321,622.12 from CNY 2,164,791,389.86 at the end of the previous year[23]. - The company's net cash and cash equivalents decreased by CNY 231,100,175.12, a decline of CNY 366,054,496.75 compared to the previous year[61]. - The company's short-term borrowings increased to ¥2,236,389,370, accounting for 28.84% of total liabilities[67]. - The company reported an investment loss of ¥12,375,570.22 from joint ventures during the reporting period[66]. Research and Development - The company reported a significant increase in R&D investment, totaling CNY 126,486,911.31, which is a 77.99% increase compared to CNY 71,063,970.91 from the previous year[61]. - The R&D work has accelerated for innovative drugs, with a focus on applications in infection, oncology, cardiovascular, and central nervous system diseases[35]. - The company has established new research institutes, including an innovative drug research institute and a traditional Chinese medicine research institute, to enhance R&D capabilities[31]. - The company is focusing on therapeutic areas such as anti-infection, neuropsychiatric, digestive, cardiovascular, and oncology in its R&D pipeline[52]. - The company has established four research institutes to drive the transformation from generic drugs to innovative drug development, enhancing its core technology system[86]. Market Strategy and Operations - The company is actively exploring new sales models and enhancing cooperation with leading domestic chains to expand market reach[35]. - The company has implemented a refined marketing strategy to improve terminal control capabilities and boost sales[35]. - The company has launched a "6523 product mix" strategy, targeting 6 types of formulations, 5 types of APIs, 2 types of intermediates, and 3 types of traditional Chinese medicine products[35]. - The company is focusing on enhancing its supply chain resources and has implemented a refined management model to improve overall operational efficiency[38]. - The company is committed to improving its R&D capabilities and product offerings to meet market demands[53]. Environmental Compliance - The company plans to maintain strict compliance with national safety and environmental regulations, ensuring that all production bases meet environmental standards[86]. - The wastewater treatment standards followed by Hainan Haiyao Co., Ltd. comply with the "Water Pollution Prevention and Control Law of the People's Republic of China" and the "Biological Engineering Pharmaceutical Industry Water Pollutant Discharge Standards" (GB 21907-2008)[101]. - The company has implemented continuous technological upgrades to strengthen energy management and pollution control, aiming for sustainable green development[86]. - The company reported a total wastewater discharge of 0.6078 tons/year with a COD concentration of 20 mg/L, meeting the secondary standards for pollutant discharge[110]. - The company has established a comprehensive waste management system to ensure compliance with environmental standards and regulations[111]. Legal and Regulatory Matters - The company is involved in multiple lawsuits, including a claim for 60 million yuan plus interest from Chongqing Jinsai, with a current interest rate of 4.35%[132]. - The company has been recognized for its social responsibility efforts, including community training projects and employment assistance in Xili Village, which has received multiple accolades[122]. - The ongoing litigation and recovery efforts are critical components of Hainan Haiyao's risk management strategy[135]. - The company is focusing on debt recovery through legal channels, indicating a strategic approach to managing financial liabilities[134]. - The company has paid a total of RMB 134.92 million as part of a repayment agreement by the end of July 2023[136]. Shareholder Information - The largest shareholder, Hainan Huatong Industrial Co., Ltd., holds 22.89% of the total shares, amounting to 296,989,889 shares[187]. - The second-largest shareholder, Shenzhen Nanfang Tongzheng Investment Co., Ltd., holds 10.28% of the total shares, amounting to 133,346,318 shares[187]. - The company reported a total of 52,830 common shareholders at the end of the reporting period[187]. - The report confirms that there are no related party transactions among the top shareholders[187]. - The company has not reported any new strategies or market expansions in the current reporting period[184].

海南海药股份有限公司独立董事 关于第十一届董事会第三次会议相关事项的独立意见 2023 年 8 月 29 日 经审阅《公司与新兴际华集团财务有限公司关联存贷款等金融业务风险评估 报告》及新兴际华集团财务有限公司（以下简称"财务公司"）相关资料，我们 认为：财务公司作为非银行金融机构，已取得中国银保监会正式颁发的金融许可 证和准予开业批复；能够按照《公司法》、《企业集团财务公司管理办法》和国家 有关金融法规等有关规定建立健全内部控制体系，未发现财务公司风险管理存在 重大缺陷；公司与财务公司关联交易价格公允，不存在损害公司、股东特别是中 小股东利益的情形。本次关联交易的审议和表决程序合规合法 ,关联董事进行了 回避表决。综上，我们同意风险评估报告的结论性意见。 特此说明。 独立董事签字：魏玉林 张强 胡秀群 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司独立 董事规则》等法律法规规范性文件，和《公司章程》的有关规定，我们作为海南 海药股份有限公司（以下简称"公司"）第十一届董事会独立董事，本着认真、 负责、独立判断的态度，核查了相关资料，经审慎分析，现就公司第十一届董事 会第三次会议相关事项发 ...

海南海药股份有限公司 法定代表人：王建平 主管会计工作负责人： 许荣义 会计机构负责人： 晏小敏 海南海药股份有限公司 海南海药股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表（续） 单位：万元 | 其他关联资金往 | 资金往来方名称 | 往来方与上市公司 | 上市公司核算 | 2 023 年期初往 | 2023 年 1-6 月往 来累计发生金额 | 2 023 年 1-6 月往来资金的 | 2023 年 1- 6 月偿还累 | 2023 年 6 月期 末往来资金余 | 往来形成 | 往来性质（经 营性往来、非经 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 来 | | 的关联关系 | 的会计科目 | 来资金余额 | （不含利息） | 利息（如有） | 计发生金额 | 额 | 原因 | 营性往来） | | 控股股东、实际 | | | | | | | | | | | | 控制人及其附属企 | | | | | | | | | | | | 业 | 海药大健康管理（北京）有限公司 | 控股子公 ...

证券代码：000566 证券简称：海南海药 公告编号：2023-055 海南海药股份有限公司 第十一届董事会第三次会议决议公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 具体内容详见同日刊载于巨潮资讯网（http//www.cninfo.com.cn）的《公 司与新兴际华集团财务有限公司关联存贷款等金融业务风险评估报告》。 一、 审议通过了《 2023 年半年度报告全文及摘要的议案》 具体内容详见同日刊载于《中国证券报》、《证券时报》、《证券日报》、《上海 证券报》及巨潮资讯网（http//www.cninfo.com.cn）的《2023 年半年度报告摘 要》和同日刊载于巨潮资讯网（http//www.cninfo.com.cn）的《2023 年半年度 报告》。 表决结果：9 票同意，0 票反对，0 票弃权 二、审议通过了《关于新兴际华集团财务有限公司的风险持续评估报告》 新兴际华集团财务有限公司（以下简称"财务公司"）严格按中国银行保险 监督管理委员会《企业集团财务公司管理办法》规定经营，根据海南海药对风险 管理的了解和评价，目前未发现财务公司的风险管理 ...

海南海药股份有限公司与新兴际华集团财务有限公司 关联存贷款等金融业务风险评估报告 海南海药股份有限公司（以下简称"公司"）2023 年 3 月 23 日召开第十届 董事会第三十四次会议及 2023 年 4 月 14 日召开的 2023 年第一次临时股东大 会，均审议通过了《关于公司与新兴际华集团财务有限公司签署<金融服务协议> 的议案》，截至 2023 年 06 月 30 日公司在新兴际华集团财务有限公司（以下简称 "财务公司"）的存款余额 38,341.84 万元。截至 2023 年 06 月 30 日财务公司为 海南海药股份有限公司提供的贷款业务余额为 33,500 万元；为公司全资子公司 海口市制药厂有限公司提供的贷款业务余额为 30,000 万元；为公司控股子公司 重庆天地药业有限责任公司提供的贷款业务余额为 3,500 万元；为公司控股子公 司湖南柳城中药饮片有限公司办理的贴现业务金额为 33.85 万元。根据财务公司 提供的有关资料和财务报表，对财务公司的经营资质、业务和风险状况进行了评 估，现将有关风险评估情况报告如下： 一、财务公司基本情况 新兴际华集团财务有限公司成立于 2021 年 1 月 ...

证券代码：000566 证券简称：海南海药 公告编号：2023-056 海南海药股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）本次会计政策变更是根据中华 人民共和国财政部（以下简称"财政部"）的相关规定进行的，无需提交公司董 事会及股东大会审议，相关会计政策变更对公司财务报表无重大影响。具体情 况如下： 一、会计政策变更情况概述： （一）会计政策变更的原因 2022 年 11 月 30 日，财政部颁布了《企业会计准则解释第 16 号》，规定 "关于单项交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会 计处理"内容自 2023 年 1 月 1 日起施行；"关于发行方分类为权益工具的金融 工具相关股利的所得税影响的会计处理"及"关于企业将以现金结算的股份支 付修改为以权益结算的股份支付的会计处理"内容自公布之日起施行。本次会 计政策变更为执行上述政策规定。 （二）会计政策变更的日期 公司根据财政部上述相关准则及通知规定，对会计政策进行相应变更，并 按以上文件规定的生效日期开始执 ...

证券代码：000566 证券简称：海南海药 公告编号：2023-054 海南海药股份有限公司 关于子公司获得政府补助的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、获得补助的基本情况 根据海口市人民政府制定的《海口市加快工业发展若干规定（2021年修订）》 的相关规定，海南海药股份有限公司（以下简称"公司"）全资子公司海口市制 药厂有限公司(以下简称"海口市制药厂")近日收到海口市科学技术工业信息化 局拨付的2021年度运输费补贴共计117.37万元，占公司最近一个会计年度经审计 的归属于上市公司股东净利润的11.16%，具体情况如下: | 获得补 | 提供补助 | 获得补助的 | 补助 | | | 是否与公司 | 是否具 | | --- | --- | --- | --- | --- | --- | --- | --- | | 助的主 | 的主体 | 原因或项目 | 形式 | 金额 | 补助依据 | 日常经营活 | 有可持 | | 体 | | | | | | 动相关 | 续性 | | | 海口市科 | | 现金 | | 《海口市加快工 | | | ...

Group 1: Financial Performance - In 2022, the company achieved revenue of CNY 1.779 billion, with a net profit of CNY 10.5157 million, marking a turnaround from previous losses [2][5][7]. - The operating cash flow for 2022 was CNY 142 million, an increase of 31.37% year-on-year, indicating significant improvement in cash flow [3]. - The company disposed of non-core assets, recovering CNY 225 million, which contributed to enhancing capital operation efficiency [2]. Group 2: Business Strategy and Development - The company focuses on core pharmaceutical operations, optimizing product structure, and enhancing sales systems to address development constraints [2]. - It has established partnerships with domestic and international pharmaceutical companies, engaging in CMO/CDMO and CRO services, which support new drug development and production [1][2]. - The company plans to expand its product and industry structure, emphasizing the development of traditional Chinese medicine and exploring opportunities in the biopharmaceutical sector [2][3]. Group 3: Market Expansion and Export Growth - In 2022, the company's international export revenue reached CNY 102 million, a year-on-year increase of 37.18% [3][6]. - The company is actively exploring new markets and channels, leveraging the opportunities presented by the Hainan Free Trade Port [3]. Group 4: Research and Development - The R&D investment for 2022 was CNY 142 million, with 10 formulation products and 3 raw material products passing the consistency evaluation for generic drugs [4]. - The company aims to enhance its R&D capabilities, focusing on areas such as anti-infection, oncology, and gastrointestinal treatments [4]. Group 5: Challenges and Risk Management - The company faced challenges due to national drug procurement policies, which led to a decline in sales prices for some products [6]. - It has implemented strict internal controls and risk management measures to mitigate potential corruption risks and ensure compliance [5][7].

证券代码：000566 证券简称：海南海药 公告编号：2023-041 海南海药股份有限公司 董 事 会 二〇二三年五月二十日 海南海药股份有限公司关于参加 2022 年度海南辖区上市公司业绩说明会的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让投资者 更准确地读懂年度报告、更全面地了解上市公司，切实提高上市公司透明度和治 理水平，海南证监局将与深圳市全景网络有限公司、海南上市公司协会联合举办 "海南辖区投资者网上集体接待日暨上市公司业绩说明会"活动，活动时间为 2023 年 5 月 26 日 14:30-17:00，平台登陆地址为：http://rs.p5w.net。 届时，海南海药股份有限公司（以下简称"公司"）主要高管人员将参加本 次活动，通过网络在线交流形式，就公司 2022 年年报披露、财务数据、公司治 理、内部控制、发展战略、经营状况、现金分红、重大事项、可持续发展等投资 者所关心的问题，与投资者进行"一对多"形式的沟通与交流。欢迎广大投资者 踊跃参与。 特此公告。 ...

海南海药股份有限公司 2023 年第一季度报告 证券代码：000566 证券简称：海南海药 公告编号：2023-033 海南海药股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 1 海南海药股份有限公司 2023 年第一季度报告 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 口是 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | (%) | | | 营业收入(元) | 495, 029, 847. 71 | 553, 628, 983, 97 | | -10.58% | | 归属于上市公司 ...